PRKG1 Gene Aortic Aneurysm, Familial Thoracic Type 8 Genetic Test in UAE | 2800 AED | DHA Guidelines

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed genetic counselors.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The PRKG1 gene NGS test detects mutations in the PRKG1 gene linked to familial thoracic aortic aneurysm type 8 (AAT8), guiding cardiologists, general physicians, and medical researchers in early surveillance and surgical planning. This analysis utilizes next-generation sequencing to examine the full coding region of PRKG1 for pathogenic variants that predispose to aortic root and ascending aortic dilation.

Pre-Test Preparation & Sample Requirements

Prior to sampling, a mandatory genetic counselling session with a DHA-licensed professional is conducted to draw a pedigree chart of family members affected with PRKG1-associated aortic aneurysm. This ensures informed consent and appropriate clinical context. Samples accepted: Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot on FTA Card. No special dietary restrictions; however, list all current medications to the phlebotomist.

Feature	Our Test (NGS)	Conventional Single-Gene Test
Precision	99.9% sensitivity; full gene coverage including deep intronic variants	Limited to known hot-spots; may miss novel mutations
Methodology	Next Generation Sequencing (Illumina® platform) with orthogonal confirmation	Sanger sequencing or MLPA
Turnaround Time	3 to 4 Weeks	6 to 8 Weeks

Physician Insight & Safety Protocols

"As a consultant in medical genetics, I emphasize that a positive PRKG1 mutation indicates a significantly elevated risk for life-threatening thoracic aortic events. Clinical correlation with echocardiography, CT angiography, and detailed family history is paramount. This test is a powerful preventive tool—never a stand-alone diagnosis—and should be interpreted within a multidisciplinary care framework."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory: Medication Continuity

⚠️ Do not discontinue prescribed medication without consulting your doctor. Abrupt cessation of beta-blockers or antihypertensives can trigger acute aortic complications.

Exclusion Criteria & Emergency Red Flags

Exclusion: Individuals under 18 years require legal guardian consent and a specialized paediatric genetics evaluation.
Exclusion: Patients with known acute aortic syndrome or hemodynamic instability—proceed to emergency care, not genetic testing.
ER Red Flags: Sudden, severe chest or back pain (tearing sensation), difficulty breathing, loss of consciousness, or stroke-like symptoms → Call 998 (UAE Emergency) immediately.

Patient FAQ & Clinical Guidance

1. What is the PRKG1 gene test, and who should consider it?

Snippet: The PRKG1 gene test detects mutations causing familial thoracic aortic aneurysm type 8, guiding life-saving monitoring and treatment.

This NGS-based analysis examines the entire coding region of PRKG1 for pathogenic variants that predispose to aortic root and ascending aortic dilation. It is strongly recommended for individuals with a family history of thoracic aortic aneurysms, sudden cardiac death, or unexplained vascular events. Clinical geneticists, cardiologists, and primary care doctors utilize results to tailor surveillance intervals, consider prophylactic surgical thresholds, and cascade screening to at-risk relatives.

2. How accurate and reliable is the NGS method for PRKG1 testing?

Snippet: Our NGS assay delivers 99.9% diagnostic sensitivity with full gene coverage, confirmed by ISO 9001:2015 accreditation.

All sequencing is performed on Illumina platforms with an average coverage depth of >200x, ensuring detection of single nucleotide variants, small indels, and copy number changes. Positive findings are orthogonally validated by Sanger sequencing or MLPA before reporting. The laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and follows DHA/MOHAP guidelines to guarantee clinical-grade results.

3. What does a positive result mean and what are the next steps?

Snippet: A positive PRKG1 mutation signals a heritable risk for thoracic aortic aneurysm, prompting cardiology referral and lifelong imaging surveillance.

A pathogenic or likely pathogenic variant confirms a genetic predisposition. Immediate steps include: (1) comprehensive cardiovascular evaluation with echocardiogram and CT/MRA angiography, (2) personalized surveillance plan (usually annually), (3) genetic counselling for family cascade testing, and (4) discussion of medical therapy (beta-blockers/angiotensin receptor blockers) to slow aortic growth. Surgical repair is considered when the aortic diameter reaches 5.0-5.5 cm, but a positive genetic result may lower the threshold. Our post-telephonic clinical guidance session helps translate the report into actionable medical management.

UAE Regulatory & Data Privacy Adherence

Your genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All laboratory processes comply with DHA standards and ISO 9001:2015 certification, ensuring strict confidentiality, secure data handling, and ethical genetic testing practices.

Clinical & Logistical Metadata

Test Name	PRKG1 Gene Sequencing (Familial Thoracic Aortic Aneurysm Type 8)
Price (AED)	2,800
Turnaround Time	3 to 4 Weeks
Sample Type / Matrix	Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA Card)
Methodology Used	Next Generation Sequencing (Illumina® Platform) with Orthogonal Validation
ICD-10-CM Code	I71.2
LOINC Code	81262-3
DHA Facility License & Laboratory Address	DHA Facility License Number: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE